Advertisement
Screener

MapLight Therapeutics, Inc. (MPLT) Return on Tangible Equity

2.8 / 5 stars · 68/120 Roast Me

MapLight Therapeutics, Inc. Return Tang Equity

Return on tangible equity is the profit a company earns on the physical and financial capital its shareholders own, leaving out goodwill and other intangible assets, shown as a percentage. It is net income divided by tangible equity, which is shareholder equity minus goodwill and intangibles; the table shows both amounts. Because acquired goodwill is removed, it runs higher than ROE for companies that grew by acquisition, and it has no meaning when goodwill exceeds equity. Goodwill and intangibles are taken at the latest reported date on or before each equity date. Quarterly points divide the trailing four quarters of net income by the balance at that quarter end; annual points divide the filed fiscal-year net income by the fiscal-year-end balance.

  • MapLight Therapeutics, Inc. return tang equity for the quarter ending 2026-06-30 was -65.99%, a 274.95% decline year-over-year.
  • MapLight Therapeutics, Inc. return tang equity for the quarter ending 2026-03-31 was -49.89%, a 232.96% decline year-over-year.
  • MapLight Therapeutics, Inc. return tang equity for the quarter ending 2025-12-31 was -35.16%, a 187.75% decline year-over-year.
  • MapLight Therapeutics, Inc. return tang equity for the quarter ending 2025-09-30 was 37.51%.
  • MapLight Therapeutics, Inc. return tang equity for fiscal 2025 was -35.16%, a 187.75% decline from fiscal 2024.
  • MapLight Therapeutics, Inc. return tang equity for fiscal 2024 was 40.07%.
Available history
2024-12-31 to 2026-06-30
Data captured

Historical Return Tang Equity

DateReturn Tang EquityNet income 12 monthTangible equity
2026-06-30-65.99%-$229.83M$348.3M
2026-03-31-49.89%-$199.48M$399.83M
2025-12-31-35.16%-$161.15M$458.37M
2025-09-3037.51%-$102.83M-$274.18M
2025-06-3037.72%-$92.43M-$245.06M
2025-03-3137.52%-$80.99M-$215.83M
2024-12-3140.07%-$77.58M-$193.63M

Annual Return Tang Equity

DateReturn Tang EquityNet income 12 monthTangible equity
2025-12-31-35.16%-$161.15M$458.37M
2024-12-3140.07%-$77.58M-$193.63M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Quoin Pharmaceuticals Ltd. (QNRX)$0.443B-17.85
CYPHERPUNK TECHNOLOGIES INC. (CYPH)United States$0.438B-75.63
ASSEMBLY BIOSCIENCES, INC. (ASMB)United States$0.481B-13,053.96
Ovid Therapeutics Inc. (OVID)United States$0.487B-14.41
PROTHENA CORP PUBLIC LTD CO (PRTA)Ireland$0.428B-11.53
DiaMedica Therapeutics Inc. (DMAC)United States$0.423B-10.11
CAPRICOR THERAPEUTICS, INC. (CAPR)United States$0.499B-10.81
Atea Pharmaceuticals, Inc. (AVIR)United States$0.414B-2.26
ARS Pharmaceuticals, Inc. (SPRY)United States$0.414B-3.70
PUMA BIOTECHNOLOGY, INC. (PBYI)United States$0.507B15.53